ERBB2 and neoplasm: Interestingly, among the 21 tumor samples analyzed, 6 had Her-2 and/or ErbB3 alterations and the 5 patients with clinical benefit belonged to this group, whereas 15 out of 15 patients without ErbB alterations had progressive disease as best response.